HIV-associated cognitive impairment before and after the advent of combination therapy
Tóm tắt
The objective of this study was to describe the occurrence of HIV dementia and neuropsychological testing abnormalities in a new cohort of HIV-seropositive individuals at high risk for HIV dementia and to compare these results to a cohort before the advent of highly active antiretroviral therapy (HAART). HAART has been associated with improvements in cognitive performance in some HIV-infected patients. However, it is uncertain whether HAART has changed the frequency of specific neurocognitive abnormalities. Baseline data from 272 HIV-seropositive subjects in the Dana cohort recruited from January, 1994, to December, 1995, and 251 HIV-seropositive subjects in the Northeastern AIDS Dementia Consortium (NEAD) cohort recruited from April, 1998, to August, 1999, were compared. Participants in both cohorts received nearly identical assessments. After adjusting for differences in age, education, gender, race, and CD4 count between the two cohorts, there were no differences in the occurrence of HIV dementia or abnormalities either 1 SD or 2 SDs below established norms for any of the neuropsychological tests. Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection.
Tài liệu tham khảo
Beck AT, Erbaugh J, Ward CH, Mock J, Mendelsohn M (1961). An inventory for measuring depression. Arch Gen Psychol 4: 561–571.
Benton AL (1955). The visual retention test. The Psychological Corporation: New York.
Bouwman FH, Skolasky RL, Hes D, Seines OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJM, McArthur JC (1998). Variable progression of HIV-associated dementia. Neurology 50: 1814–1820.
Bozette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, Emmons CA, Senterfitt JW, Berk ML, Morton SC, Shapiro MF (1998). The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 339: 1897–1904.
Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997). Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731–1738.
Centers for Disease Control and Prevention (1996). HIV/AIDS surveillance report. US Department of Health and Human Services Public Health Service: Atlanta, GA.
Chang L, Ernst T, Leonido-Yee M, Witt M, Speck O, Walot I, Miller EN (1999). Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 53: 782–789.
Childs EA, Lyles RH, Seines OA, Chen B, Miller EN, Cohen BA, Backer JT, Mellors J, McArthur JC (1999). Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52: 607–613.
Concha M, Seines OA, McArthur JC, Nance-Sproson T, Updike ML, Royal W III, Solomon L, Vlahov D (1995). Normative data for a brief neuropsychologic test battery in a cohort of injecting drug users. Intl J Addictions 30: 823–841.
The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (1996). Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology 47: 1247–1253.
Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA, The HIV Neurobehavioral Research Center Group (1997). Cerebrospinal fluid human immundeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42: 679–688.
Fahn S, Jenner P, Marsden C, Teykhenne P (1987). Recent developments in Parkinson’s disease. Macmillan Healthcare Information: Old Tappan, NJ, p 153.
Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B (1977). Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11: F113-F116.
Flowers KA, Robertson C. (1985). The effects of Parkinson’s disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry 48: 517–529.
Janssen RS, Cornblath DR, Epstein GL, Foa RP, McArthur JC, Price RW (1991). Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-l) infection: Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 41: 778–785.
Karnofsky DA, Abelman WH, Craver LF, Burchenal JH (1948). The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–656.
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963). Studies of illness in the aged: The index of ADL. JAMA 183: 914–919.
Klove H (1963). Clinical neuropsychology. Med Clin North Am 46: 1647–1658.
Lawton MP, Brody EM (1969). Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9: 179–186.
McArthur JC, Hoover DR, Bacellar, Miller EN, Cohen BA, Becker JT, Graham NMH, McArthur JH, Seines OA, Jacobson LP, Visscher BR, Concha M, Saah A (1993). Dementia in AIDS patients: Incidence and risk factors. Neurology 43: 2245–2252.
McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER (1997). Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42: 689–698.
Miller EN, Satz P, Visscher B (1991). Computerized and conventional neuropsychological assessment of HIV-1 infected homosexual men. Neurology 41: 1608–1616.
Nelson HE (1982). The National Adult Reading Test (NART): Test manual. The National Hospital for Nervous Diseases: London.
Nelson HE, O’Connell A. (1978). Dementia: The estimation of premorbid intelligence levels using the National Adult Reading Test. Cortex 14: 234–244.
Price RW, Brew BJ (1988). The AIDS dementia complex. J Infect Dis 158: 1079–1083.
Radloff LL (1977). The CES-D: A self-report depression scale for research in the general population. Appl Psychol Meas 1: 385–401.
Reitan R (1958). Validity of the Trail Making test as an indicator of organic brain damage. Percept Motor Skills 8: 271–276.
Reitan R (1979). Manual for administration of neuropsychological test batteries for adults and children. Neuropsychologial Laboratory: Tucson, AZ.
Rey A (1941). L’examen psychological dans les cas d’encephalopathie traumatique. Arch Psychol 28: 286–340.
Sacktor NC, Lyles RH, Skolasky R, Kleeberger C, Seines OA, Miller EN, Becker JT, Cohen B, McArthur JC, The Multicenter AIDS Cohort Study (1999). HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy. Neurology 52: A252–253.
Sacktor NC, Skolasky RL, Lyles RH, Esposito D, Seines OA, McArthur JC (2000a). Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J NeuroVirol 6: 84–88.
Sacktor NC, Pomper MG, Ilorska A, Barker PB, McArthur JC (2000b). Magnetic resonance spectroscopic imaging measures metabolite changes during therapy for HIV-associated cognitive impairment. Neurology 54: A252.
Seines OA, Jacobson L, Machado AM, Becker JT, Wesch J, Miller EN, Visscher B, McArthur JC (1991). Normative data for a brief neuropsychological screening battery. Percept Mot Skills 73: 539–550.
Stewart AL, Ware JE (1993). Measuring function and well-being: The Medical Outcomes Study approach. Duke University Press: Durham, NC.
Wechsler D (1981). Wechsler Adult Intelligence Scale— Revised. The Psychological Corporation: New York.